What type of study is this?

This is a Phase 2 study (also classified as: Human Clinical Trial).

August 22, 2025

Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Steady-state plasma levels of TP-0903 indicate different toxicity responses in patients.
Patients with higher plasma levels showed distinct decreases in absolute neutrophil counts and platelets.
The analysis compared pharmacokinetics in both Responders and Non-responders, revealing crucial results.
Findings may influence treatment strategies for acute myeloid leukemia while managing toxicity.

No takes yet. Share an insight, caveat, or question.

Clinical study examines pharmacokinetics and toxicity response in acute myeloid leukemia patients ≥60 years, suggesting key insights.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark